Decreased levels of the brain specific 24S-hydroxycholesterol and cholesterol precursors in serum of multiple sclerosis patients

Neuroscience Letters

Volumn 347, Issue 3, 2003, Pages 159-162

  Teunissen, C E ^a   Dijkstra, C D ^a   Polman, C H ^a   Hoogervorst, E L J ^a   Von Bergmann, K ^b   Lutjohann D ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF BONN   (Germany)

Author keywords

24S hydroxycholesterol; Cholesterol synthesis; Multiple sclerosis; Serum markers

Indexed keywords

24 HYDROXYCHOLESTEROL; CHOLESTEROL; CHOLESTEROL DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OXYSTEROL; STEROL; UNCLASSIFIED DRUG; 24-HYDROXYCHOLESTEROL; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HOMEOSTASIS; HUMAN; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RELAPSE; TREATMENT OUTCOME; BLOOD; BRAIN; CHEMISTRY; METABOLISM; MIDDLE AGED; STEREOISOMERISM;

ADULT; AGED; BIOLOGICAL MARKERS; BRAIN; CHOLESTEROL; FEMALE; HUMANS; HYDROXYCHOLESTEROLS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; STEREOISOMERISM;

EID: 0041589132     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(03)00667-0     Document Type: Article

References (15)

1. Björkhem I., Lütjohann D., Diczfalusy U., Stahle L., Ahlborg G., Wahren J. Cholesterol homeostasis in human brain: turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation. J. Lipid Res. 39:1998;1594-1600.
2. Bretillon L., Lütjohann D., Stahle L., Widhe T., Bindl L., Eggertsen G., Diczfalusy U., Björkhem I. Plasma levels of 24S-hydroxycholesterol reflect the balance between cerebral production and hepatic metabolism and are inversely related to body surface. J. Lipid Res. 41:2000;840-845.
3. Bruck W., Lucchinetti C., Lassmann H. The pathology of primary progressive multiple sclerosis. Mult. Scler. 8:2002;93-97.
4. Kurtzke J.F. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 33:1983;1444-1452.
5. Leoni V., Masterman T., Diczfalusy U., De Luca G., Hillert J., Björkhem I. Changes in human plasma levels of the brain specific oxysterol 24S-hydroxycholesterol during progression of multiple sclerosis. Neurosci. Lett. 331:2002;163.
6. Lund E.G., Guileyardo J.M., Russell D.W. cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. Proc. Natl. Acad. Sci. USA. 96:1999;7238-7243.
7. Lütjohann D., Breuer O., Ahlborg G., Nennesmo I., Siden A., Diczfalusy U., Björkhem I. Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation. Proc. Natl. Acad. Sci. USA. 93:1996;9799-9804.
8. Lütjohann D., Papassotiropoulos A., Björkhem I., Locatelli S., Bagli M., Oehring R.D., Schlegel U., Jessen F., Rao M.L., von Bergmann K., Heun R. Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. J. Lipid Res. 41:2000;195-198.
9. Miettinen T.A., Tilvis R.S., Kesaniemi Y.A. Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population. Am. J. Epidemiol. 131:1990;20-31.
10. Miller D.H., Barkhof F., Frank J.A., Parker G.J., Thompson A.J. Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain. 125:2002;1676-1695.
11. Neuhaus O., Strasser-Fuchs S., Fazekas F., Kieseier B.C., Niederwieser G., Hartung H.P., Archelos J.J. Statins as immunomodulators: comparison with interferon-beta1b in MS. Neurology. 59:2002;990-997.
12. Simons M., Schwarzler F., Lütjohann D., von Bergmann K., Beyreuther K., Dichgans J., Wormstall H., Hartmann T., Schulz J.B. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial. Ann. Neurol. 52:2002;346-350.
13. Sperling R.A., Guttmann C.R., Hohol M.J., Warfield S.K., Jakab M., Parente M., Diamond E.L., Daffner K.R., Olek M.J., Orav E.J., Kikinis R., Jolesz F.A., Weiner H.L. Regional magnetic resonance imaging lesion burden and cognitive function in multiple sclerosis: a longitudinal study. Arch. Neurol. 58:2001;115-121.
14. Teunissen C.E., de Vente J., von Bergmann K., Bosma H., van Boxtel M.P.J., De Bruijn C., Jolles J., Steinbusch H.W.M., Lütjohann D. Serum cholesterol, precursors and metabolites and cognitive performance in an aging population. Neurobiol. Aging. 24:2003;147-155.
15. Youssef S., Stuve O., Patarroyo J.C., Ruiz P.J., Radosevich J.L., Hur E.M., Bravo M., Mitchell D.J., Sobel R.A., Steinman L., Zamvil S.S. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 420:2002;78-84.